This is a preview of subscription content, log in via an institution to check access.
Reference
Institute for Clinical and Economic Review. Institute for Clinical and Economic Review Posts Updated Economic Analyses for PCSK9 Inhibitor Evolocumab, Finds Less Favorable Cost-Effectiveness. Internet Document : 11 Sep 2017. Available from: URL: https://icer-review.org/announcements/pcsk9-neu/
Rights and permissions
About this article
Cite this article
Cost effectiveness of evolocumab less favourable in ICER update. PharmacoEcon Outcomes News 787, 1 (2017). https://doi.org/10.1007/s40274-017-4329-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-4329-5